É. Radeczky

Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial.

E. Kerwin, E. Bleecker, D. Bernstein, 2017, The Lancet. Respiratory medicine.

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.

H. Watz, A. Kirsten, B. Bálint, 2015, Pulmonary pharmacology & therapeutics.